Colorectal Cancer Clinical Trial
— EARDISOfficial title:
Proof-of-concept Study of Blood Markers of Tumor Dissemination in Patients With Versus Without Intestinal Polyps
The study authors hypothesize that in patients with intestinal polyps, tumor cells could disseminate and circulating factors could be secreted by the polyp. These two parameters could become biomarkers to refine the follow-up of patients and to establish targeted therapeutic strategies.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | February 2025 |
Est. primary completion date | February 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient to be examined by colonoscopy - The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: - The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study - The subject signals their opposition to participate in the study - It is impossible to give the subject informed information - The patient is under safeguard of justice or state guardianship - Patient pregnant or breastfeeding - History of proven cancerous disease - Patient followed for a chronic inflammatory bowel disease |
Country | Name | City | State |
---|---|---|---|
France | CHU de Nîmes | Nîmes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dissemination of circulating tumor cells in blood samples from patients with intestinal polyps compared to patients without polyps | Number of disseminated circulating tumor cells found on the ANGLE Parsortix™ system | Day 0 | |
Secondary | Concentration of Macrophage Colony Stimulating Factor (M-CSF) in the blood samples between groups | ng/mL, measured by Enzyme-Linked ImmunoSorbent Assay | Day 0 | |
Secondary | Concentration of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in the blood samples between groups. | ng/mL, measured by Enzyme-Linked ImmunoSorbent Assay | Day 0 | |
Secondary | Concentration of Chemokine ligand 2 (CCL-2) in the blood samples between groups. | ng/mL, measured by Enzyme-Linked ImmunoSorbent Assay | Day 0 | |
Secondary | Concentration of keratinocyte-derived cytokine (CXCL-1) in the blood samples between groups | ng/mL, measured by Enzyme-Linked ImmunoSorbent Assay | Day 0 | |
Secondary | Concentration of Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) in the blood samples between groups | ng/mL, measured by Enzyme-Linked ImmunoSorbent Assay | Day 0 | |
Secondary | Concentration of Stromal cell-Derived Factor 1 (SDF-1) in the blood samples between groups | ng/mL, measured by Enzyme-Linked ImmunoSorbent Assay | Day 0 | |
Secondary | Anti-aggregant therapy according to presence of circulating tumor cells, cytokine presence and presence of polyp | Yes/no | Day 0 | |
Secondary | Anti-coagulant therapy according to presence of circulating tumor cells, cytokine presence and presence of polyp | Yes/no | Day 0 | |
Secondary | Known intestinal pathology according to presence of circulating tumor cells, cytokine presence and presence of polyp | Yes/no | Day 0 | |
Secondary | Reason for screening colonoscopy according to presence of circulating tumor cells, cytokine presence and presence of polyp | Fecal immunochemical test positive / Personal history of colonic adenoma / Family history of colonic adenoma / Personal history of colorectal cancer / Family history of colorectal cancer / Rectal symptoms | Day 0 | |
Secondary | Screening colonoscopy operator (inter-operator tumor detection rate) according to presence of circulating tumor cells, cytokine presence and presence of polyp | Day 0 | ||
Secondary | Quality of the preparation according to presence of circulating tumor cells, cytokine presence and presence of polyp | Boston classification: ranked from 0 to 3 for each colonic segment explored | Day 0 | |
Secondary | Caecal intubation rate according to presence of circulating tumor cells, cytokine presence and presence of polyp | classed as complete colonoscopy after visualization of the caecal floor | Day 0 | |
Secondary | Per-surgical complications according to presence of circulating tumor cells, cytokine presence and presence of polyp | Post-polypectomy bleeding / Perforation / Incomplete colonoscopy / No complications | Day 0 | |
Secondary | Total number of colonic adenomas visualized according to presence of circulating tumor cells, cytokine presence and presence of polyp | Number | Day 0 | |
Secondary | Total number of histologically validated resected colonic adenomas according to presence of circulating tumor cells, cytokine presence and presence of polyp | Number | Day 0 | |
Secondary | Size of resected adenomas according to presence of circulating tumor cells, cytokine presence and presence of polyp | < 5mm / 5 - 10mm / > 10mm | Day 0 | |
Secondary | Location of resected adenomas according to presence of circulating tumor cells, cytokine presence and presence of polyp | Rectum / Sigmoid / Left Colon / Transverse Colon / Right Colon / Caecum | Day 0 | |
Secondary | Morphology of resected adenomas according to presence of circulating tumor cells, cytokine presence and presence of polyp | Paris classification: 0-Is / 0-Ip / 0-IIa / 0-IIb / 0-IIc / 0-III | Day 0 | |
Secondary | Method of resected adenomas according to presence of circulating tumor cells, cytokine presence and presence of polyp | Biopsy forceps / Cold loop / Diathermic loop / Mucosectomy / Unresected (Suspected Cancer, Unresectable in ambulatory) | Day 0 | |
Secondary | Recovery of the adenoma after resection according to presence of circulating tumor cells, cytokine presence and presence of polyp | Yes/no | Day 0 | |
Secondary | Histology of resected adenomas according to presence of circulating tumor cells, cytokine presence and presence of polyp | Vienna classification: Nonspecific (Food Residue, Normal Mucosa or Colonic Fold) / Adenoma in Low Grade Dysplasia / Adenoma in High Grade Dysplasia / Cancer - Transformed Adenoma / Scalloped Adenoma / Hyperplastic Polyp. | Day 0 | |
Secondary | Location of resected adenomas according to presence of circulating tumor cells, cytokine presence and membrane marker expression | Rectum / Sigmoid / Left Colon / Transverse Colon / Right Colon / Caecum | Day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |